Juliane Bubeck Wardenburg Selected Research

Staphylococcal Pneumonia

1/2010	Prevention and treatment of Staphylococcus aureus pneumonia with a beta-cyclodextrin derivative.
9/2009	A point mutation in the agr locus rather than expression of the Panton-Valentine leukocidin caused previously reported phenotypes in Staphylococcus aureus pneumonia and gene regulation.
7/2009	Anti-alpha-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia.
2/2008	Vaccine protection against Staphylococcus aureus pneumonia.
12/2007	Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia.
2/2007	Surface proteins and exotoxins are required for the pathogenesis of Staphylococcus aureus pneumonia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Juliane Bubeck Wardenburg Research Topics

Disease

11	Infections 01/2018 - 09/2006
8	Pneumonia (Pneumonitis) 01/2019 - 02/2007
7	Sepsis (Septicemia) 01/2019 - 08/2012
6	Staphylococcal Pneumonia 01/2010 - 02/2007
2	Soft Tissue Infections 01/2020 - 09/2011
2	Critical Illness (Critically Ill) 01/2019 - 02/2017
2	Vascular System Injuries 01/2019 - 08/2012
2	Staphylococcal Infections 02/2017 - 09/2006
2	Necrosis 06/2013 - 10/2009
2	Abscess 10/2012 - 09/2006
1	Human Influenza (Influenza) 01/2019
1	Coinfection 01/2019
1	Acute Lung Injury 01/2019
1	Pathologic Neovascularization 01/2019
1	Leukopenia 01/2019
1	Multiple Organ Failure (MODS) 03/2017
1	Disease Progression 02/2017
1	Virus Diseases (Viral Diseases) 12/2016
1	Neoplasms (Cancer) 01/2016
1	Colitis 01/2016
1	Chronic Kidney Failure (Chronic Renal Failure) 10/2012
1	Lung Injury 09/2012
1	Necrotizing Pneumonia 10/2009
1	Inflammation (Inflammations) 10/2009

Drug/Important Bio-Agent (IBA)

11	Hemolysin Proteins (Hemolysins)IBA 01/2018 - 12/2007
6	Virulence Factors (Pathogenicity Factors)IBA 06/2015 - 07/2009
6	Cytotoxins (Cytolysins)IBA 01/2014 - 07/2009
3	Panton-Valentine leukocidinIBA 09/2011 - 12/2007
3	VaccinesIBA 01/2010 - 02/2008
2	Methicillin (Metin)FDA Link 01/2020 - 01/2010
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2019 - 01/2010
2	AntigensIBA 12/2016 - 02/2008
2	EpitopesIBA 01/2016 - 07/2009
1	A-factor (Streptomyces)IBA 01/2020
1	N 30IBA 01/2019
1	Notch ReceptorsIBA 01/2019
1	Vancomycin FDA LinkGeneric 01/2019
1	Leukocidins (Leukocidin)IBA 01/2019
1	Glucose (Dextrose)FDA LinkGeneric 03/2017
1	Pharmaceutical PreparationsIBA 02/2017
1	Bacteroides fragilis toxinIBA 01/2016
1	fragilysinIBA 01/2016
1	Enterotoxins (Enterotoxin)IBA 01/2016
1	Peptide Hydrolases (Proteases)FDA Link 01/2016
1	Bacterial ToxinsIBA 06/2015
1	AntibodiesIBA 06/2013
1	FibrinIBA 10/2012
1	CollagenIBA 10/2012
1	staphylococcal delta toxinIBA 09/2011
1	Peptides (Polypeptides)IBA 09/2011
1	betadex (beta-cyclodextrin)IBA 01/2010
1	Proteins (Proteins, Gene)FDA Link 10/2009
1	ChromatinIBA 10/2009
1	HMGB1 Protein (HMG1)IBA 10/2009
1	InflammasomesIBA 10/2009
1	Monoclonal AntibodiesIBA 07/2009
1	Immunoglobulin G (IgG)IBA 02/2008
1	Membrane Proteins (Integral Membrane Proteins)IBA 02/2007
1	ExotoxinsIBA 02/2007
1	Lipoproteins (Lipoprotein)IBA 09/2006
1	Toll-Like Receptors (Toll-Like Receptor)IBA 09/2006
1	AcidsIBA 09/2006
1	Peptidoglycan (Murein)IBA 09/2006

Therapy/Procedure

5	Therapeutics 01/2019 - 07/2009
1	Extracorporeal Membrane Oxygenation 01/2019
1	Critical Care (Surgical Intensive Care) 02/2017
1	Continuous Ambulatory Peritoneal Dialysis (CAPD) 10/2012